Clinical Research Directory
Browse clinical research sites, groups, and studies.
AI-ECG Screening for Early Heart Failure Diagnosis
Sponsor: Antonio Luiz Pinho Ribeiro
Summary
The goal of this parallel-group cluster randomized clinical trial is to evaluate whether opportunistic screening for left ventricular systolic dysfunction (LVSD), using an artificial intelligence algorithm applied to electrocardiograms (AI-ECG), increases the detection of previously unrecognized LVSD among adults aged ≥40 years receiving routine care in primary healthcare centers within the Brazilian Public Health System. LVSD is a key finding in the diagnosis of heart failure with reduced ejection fraction (HFrEF), a condition for which effective guideline-directed medical therapies are available but which remains underdiagnosed and undertreated. The study will also evaluate the effects of AI-ECG screening on clinical management, healthcare utilization, implementation outcomes, and healthcare costs. The main questions this study aims to answer are: 1. Does adding AI-ECG screening to usual clinical assessment increase the proportion of patients with newly identified LVSD (left ventricular ejection fraction \<50%) within six months compared with clinical assessment alone? 2. Does AI-ECG screening improve the use of echocardiography, the recognition by primary care teams, and the initiation or optimization of guideline-directed medical therapy for HFrEF? 3. How do LVSD detection rates differ between patients identified through AI-ECG screening alone and those identified through clinical suspicion alone? 4. Is this screening strategy feasible, acceptable, and cost-effective when implemented in primary healthcare? Primary healthcare centers will be randomized to either an intervention group, in which AI-ECG screening results will be provided alongside the standard ECG report, or a control group receiving usual care without AI-ECG results. Participants will: 1. Undergo a routine 12-lead electrocardiogram (ECG), as clinically indicated by their primary care physician. 2. Be referred for echocardiography based on clinical suspicion of LVSD in both groups or, additionally, a positive AI-ECG screening result in the intervention group. 3. Receive educational materials about HFrEF if newly diagnosed, while participating healthcare professionals will receive educational interventions on heart failure diagnosis and management. 4. Complete questionnaires evaluating educational interventions, when applicable. 5. Be followed for six months to assess newly identified LVSD, treatment initiation and optimization, healthcare utilization (including emergency visits and hospitalizations), mortality, implementation outcomes, and healthcare costs.
Official title: Validated AI-ECG Screening and Intervention for Optimizing Heart Failure Diagnosis
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
5400
Start Date
2026-11-19
Completion Date
2028-05
Last Updated
2026-11-20
Healthy Volunteers
Yes
Interventions
Artificial Intelligence applied to the electrocardiogram to identify left ventricular systolic dysfunction
AI-ECG results will be generated in real time through an application programming interface (API) connected to Yale University's Cardiovascular Data Science (CarDS) Lab. The AI-ECG algorithm was developed by the Yale CarDS Lab and previously validated for detecting LVSD (Sangha et al. Circulation. 2023;148:765-777. doi: 10.1161/CIRCULATIONAHA.122.062646). A positive AI-ECG screening result will be generated when the predicted probability of LVSD exceeds a predefined threshold of 0.10. This threshold was selected to achieve a sensitivity greater than 90% in the original internal validation study to detect left ventricular ejection fraction (LVEF)\<40%. In the present study, it will be used to detect a LVEF\<50%, as current guidelines uses this threshold for LVSD, which leads to clinical actions.
Locations (1)
Telehealth Center at Hospital das Clínicas
Belo Horizonte, Minas Gerais, Brazil